Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Nov;63(11):e289-e295.
doi: 10.1111/ijd.17344. Epub 2024 Jun 21.

Treatment of atopic dermatitis with abrocitinib in real practice in Spain: efficacy and safety results from a 24-week multicenter study

Jose Carlos Armario-Hita #  1 , Jose Juan Pereyra-Rodriguez #  2   3 , Alicia González-Quesada  4 , Pedro Herranz  5 , Ricardo Suarez  6 , Manuel Galan-Gutiérrez  7 , Mercedes Rodríguez-Serna  8 , Javier Ortiz de Frutos  9 , José Manuel Carrascosa  10 , Esther Serra-Baldrich  11 , Mariano Ara-Martin  12 , Ignasi Figueras-Nart  13 , Juan Francisco Silvestre  14 , Violeta Zaragoza-Ninet  15 , Ricardo Ruiz-Villaverde  16
Affiliations
Multicenter Study

Treatment of atopic dermatitis with abrocitinib in real practice in Spain: efficacy and safety results from a 24-week multicenter study

Jose Carlos Armario-Hita et al. Int J Dermatol. 2024 Nov.

Abstract

Background: Abrocitinib, a selective JAK 1 inhibitor, was recently approved in Europe. Despite its approval, real-world data on its efficacy and safety in treating moderate-to-severe atopic dermatitis (AD) remains limited.

Objectives: This study aimed to evaluate the short-term effectiveness and safety of abrocitinib in a real-life setting for patients with moderate-to-severe AD.

Methods: We conducted a retrospective multicenter study involving adult patients with moderate-to-severe AD who started abrocitinib treatment between May 1, 2023, and September 30, 2023, in 15 Spanish hospitals. Treatment doses were 100 or 200 mg daily, based on clinical assessment. Data collection included patient demographics, AD history, comorbidities, previous treatments, and disease severity indicators such as SCORing atopic dermatitis (SCORAD), Eczema Area and Severity Index (EASI), body surface area, and Peak Pruritus NRS scores at baseline, 4, 12, and 24 weeks. Quality of life was measured using the Dermatology Life Quality Index (DLQI), and safety was assessed by monitoring adverse reactions and various biochemical parameters.

Results: The cohort comprised 76 patients with an average age of 33.93 years; 57.89% were male. Before abrocitinib, 36.84% were naïve to advanced therapies. The baseline mean scores were SCORAD 47.04, EASI 21.79, and DLQI 15.01. At Week 24, there were significant improvements: EASI was reduced to 2.81, and 70.58% of the patients achieved EASI 75. However, 18.42% discontinued treatment mainly due to inefficacy or adverse effects. The safety profile was favorable, with 22.37% reporting mild adverse events (AEs) and one serious case of cutaneous lymphoma.

Conclusions: This first Spanish series assessing abrocitinib in real-world conditions reveals a significant improvement in AD symptoms and quality of life in a range of severity and prior treatment failures. Abrocitinib was well-tolerated, with few serious AEs, highlighting its potential as an effective treatment option for AD.

Keywords: JAK inhibitors; Spain; abrocitinib; atopic dermatitis; treatment.

PubMed Disclaimer

References

    1. Silvestre Salvador JF, Romero‐Pérez D, Encabo‐Durán B. Atopic dermatitis in adults: a diagnostic challenge. J Investig Allergol Clin Immunol. 2017;27(2):78–88.
    1. Sicras‐Mainar A, Navarro‐Artieda R, Armario‐Hita JC. Severe atopic dermatitis in Spain: a real‐life observational study. Ther Clin Risk Manag. 2019;15:1393–1401.
    1. Wollenberg A, Christen‐Zäch S, Taieb A, Paul C, Thyssen JP, de Bruin‐Weller M, et al. European Task Force on Atopic Dermatitis/EADV Eczema Task Force. ETFAD/EADV Eczema Task Force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020;34(12):2717–2744.
    1. Simpson EL, Bruin‐Weller M, Flohr C, Ardern‐Jones MR, Barbarot S, Deleuran M, et al. When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. J Am Acad Dermatol. 2017;77(4):623–633.
    1. Damiani G, Calzavara‐Pinton P, Stingeni L, Hansel K, Cusano F, “Skin Allergy” Group of SIDeMaST; “ADOI” (Associazione Dermatologi Ospedalieri Italiani); “SIDAPA” (Società Italiana di Dermatologia Allergologica, Professionale e Ambientale); Pigatto PDM. Italian guidelines for therapy of atopic dermatitis‐Adapted from consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis). Dermatol Ther. 2019;32(6):e13121.

Publication types

LinkOut - more resources